ReviewJournal of translational medicine2025
Targeting immune microenvironment in cervical cancer: current research and advances.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.International journal of molecular sciences · 2026Article
- Article
- Article
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
- Mechanism of Xiao-ai-fei Honey Ointment, a Traditional Uyghur Multi-Ingredient Medicinal Preparation, Against Cervical Cancer Based on Network Pharmacology and In Vitro Evaluation of Anti-Cancer Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- TAMs in the Gynecological Tumor Microenvironment: Insights from Cross-Cancer Studies for Immunotherapy.Cancers · 2026Review
- Design of Experiments in the Formulation and Characterization of 3D-Printed Vaginal Films Loaded with Curcumin Solid Lipid Nanoparticles for Cervical Dysplasia.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes.Frontiers in immunology · 2026Article
- Dihydroalterperylenol from endophytic fungusMolecular medicine reports · 2026Article
- Lymphangiogenesis-related gene signature-based risk model for prognostic assessment of cervical cancer: immune-metabolic characterization and molecular subtype analysis.Frontiers in genetics · 2026Article
- Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review).Oncology letters · 2026Review
- Innovations in HPV vaccination and their role in global cervical cancer control: a review.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Deciphering HPV-Associated Immune Evasion in Cervical Cancer Through Multi-Omics Profiling and Computational Screening.Analytical cellular pathology (Amsterdam) · 2026Article
- Immune heterogeneity and therapeutic resistance in gynecological malignancies.Frontiers in immunology · 2026Review
- Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncology research · 2026Review
- Review
- siRNA and mRNA-Based Preventive and Therapeutic Strategies for HPV-Induced Cervical Cancer.Advanced pharmaceutical bulletin · 2025Review
- Licoricidin Enhances Paclitaxel-induced Apoptosis Through Endoplasmic Reticulum Stress in Human Cervical Cancer Cells.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The immune microenvironment plays a critical role in pathogenesis and treatment response of cervical cancer. This review comprehensively examines the cellular and molecular components of the tumor immune microenvironment (TIME) in cervical cancer, encompassing patterns of immune cell infiltration (T cells, B cells, NK cells, DCs, TAMs), immune checkpoint molecules, and cytokine/chemokine networks. We emphasize recent advances in understanding TIME heterogeneity, enabled by high-resolution spatial mapping and single-cell sequencing technologies, focusing specifically on differences across disease stages and treatment approaches. The review systematically evaluates immunotherapeutic strategies, such as immune checkpoint inhibitors, adoptive cell therapies, and therapeutic vaccines, discussing their mechanisms of action, clinical efficacy, and challenges. By synthesizing insights from both preclinical and clinical studies, our aim is to offer a translational perspective on targeting the TIME to enhance outcomes for cervical cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.